• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Charlie Fazio on the Uncertainty of Transitioning to Value-Based Care

Video

Charlie Fazio, MD, senior vice president and medical director of HealthPartners discusses the uncertainty felt by practices as the industry moves from fee-for-service to value-based care.

Charlie Fazio, MD, senior vice president and medical director of HealthPartners discusses the uncertainty felt by practices as the industry moves from fee-for-service to value-based care

Transcript (slightly modified)

How do physicians balance the fact that the industry is moving toward value-based care, but they are mostly still practicing in a fee-for-service environment?

There’s a lot of uncertainty as people live in a fee-for-service world and we start to talk about a world where there might be more payments based on population. It’s tough for a practice to figure out "when do I go from A to B?" and so for a while they live with the ambiguity, they try to run both models even though at the same time, I want to treat everybody I see in the course of a day, the same way, according to the same model, without worrying about how I’m being paid for them. You can’t possibly keep track of all that.

So, in a lot of ways I think it’s important for a practice to think through: how do I coordinate the various contracts I have? How do I move more in the direction of population-based care? When will it be safe for me to think through: I want to run this as efficiently as I can, I want to run this based on cost rather than on revenue, and I want to go all-in on the team version.

That’s a tough decision and I think it’s incumbent on all of us. It’s important to all of us and we’ll all benefit from helping practices figure out how to go there.

Related Videos
Most employees are unprepared to shop for coverage on their own, underscoring the need for stronger decision tools and consumer protections.
Experts warn that ICHRAs could either stabilize or destabilize the individual market, depending on which workers employers shift into these plans.
Aleata Postell, SVP of pharmacy business development, CenterWell Pharmacy
ASCO GI 2026 Recap
Jo Varshney, PhD, DVM, CEO and founder of VeriSIM Life
Dr Marco del Riccio
Bhavana (Tina) Bhatnagar, DO, West Virginia University Cancer Institute at Wheeling Hospital
Dr Debra Patt
Dr Marco del Riccio
Where patients live may shape outcomes in hypertrophic cardiomyopathy, with SDOH linked to higher risks of heart failure and arrhythmias.
© 2026 MJH Life Sciences
AJMC®
All rights reserved.